Clostridium difficile is an anaerobic, spore-forming Gram-positive bacillus that is able to colonize and proliferate in the human gut, especially following changes in the indigenous colonic microbiota after antibiotic use 1 . The period from spore ingestion to symptom onset is variable but typically short; one study published in 2012 found that 82% of CDIs occurred within 4 weeks of a potential donor infection 2 . However, the timing and development of clinical disease is dependent on microbiological, biochemical and immune factors present in the patient's bowel (FIG. 1) . Importantly, human ingestion of spores does not always result in symptomatic infection. The clinical outcome after spore acquisition is variable and ranges from transient colonization of the gut to fulminant disease 3, 4 . Asymptomatic carriers of C. difficile provide a potential reservoir for onward transmission, especially within a hospital population 4 . C. difficile is a genetically diverse species 5 , including both pathogenic (toxin-producing) and non-pathogenic strains (FIG. 1) . Thus, diagnostic tests for CDI should ideally detect only strains (or their toxins) that have the potential to cause disease. Clinical infection develops in an individual when successful germination of C. difficile spores results in toxin production within the gut lumen. The actions of two protein exotoxins, TcdA (toxin A) and TcdB (toxin B), disrupt colonic epithelial cells and stimulate the release of pro-inflammatory cytokines and chemokines 6 . This process leads to an intense inflammatory response causing acute inflammation of the large intestine 6, 7 . The spectrum of clinical disease ranges from mild diarrhoea to toxic megacolon (grossly dilated bowel), colonic perforation and death. Research suggests that both strain characteristics and the host's immune response influence CDI severity, recurrence risk and mortality [7] [8] [9] . Several advances have contributed to a new understanding of CDI. The epidemiology of CDI is now recognized to be heterogeneous in terms of incidence and strain types reflecting different stages of epidemic spread 10 Abstract | Clostridium difficile infection (CDI) continues to affect patients in hospitals and communities worldwide. The spectrum of clinical disease ranges from mild diarrhoea to toxic megacolon, colonic perforation and death. However, this bacterium might also be carried asymptomatically in the gut, potentially leading to 'silent' onward transmission. Modern technologies, such as whole-genome sequencing and multi-locus variable-number tandem-repeat analysis, are helping to track C. difficile transmission across health-care facilities, countries and continents, offering the potential to illuminate previously under-recognized sources of infection. These typing strategies have also demonstrated heterogeneity in terms of CDI incidence and strain types reflecting different stages of epidemic spread. However, comparison of CDI epidemiology, particularly between countries, is challenging due to wide-ranging approaches to sampling and testing. Diagnostic strategies for C. difficile are complicated both by the wide range of bacterial targets and tests available and the need to differentiate between toxin-producing and non-toxigenic strains. Multistep diagnostic algorithms have been recommended to improve sensitivity and specificity. In this Review, we describe the latest advances in the understanding of C. difficile epidemiology, transmission and diagnosis, and discuss the effect of these developments on the clinical management of CDI.
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The period from spore ingestion to symptom onset is variable but typically short; one study published in 2012 found that 82% of CDIs occurred within 4 weeks of a potential donor infection 2 . However, the timing and development of clinical disease is dependent on microbiological, biochemical and immune factors present in the patient's bowel (FIG. 1) . Importantly, human ingestion of spores does not always result in symptomatic infection. The clinical outcome after spore acquisition is variable and ranges from transient colonization of the gut to fulminant disease 3, 4 . Asymptomatic carriers of C. difficile provide a potential reservoir for onward transmission, especially within a hospital population 4 . C. difficile is a genetically diverse species 5 , including both pathogenic (toxin-producing) and non-pathogenic strains (FIG. 1) . Thus, diagnostic tests for CDI should ideally detect only strains (or their toxins) that have the potential to cause disease. Clinical infection develops in an individual when successful germination of C. difficile spores results in toxin production within the gut lumen. The actions of two protein exotoxins, TcdA (toxin A) and TcdB (toxin B), disrupt colonic epithelial cells and stimulate the release of pro-inflammatory cytokines and chemokines 6 . This process leads to an intense inflammatory response causing acute inflammation of the large intestine 6, 7 . The spectrum of clinical disease ranges from mild diarrhoea to toxic megacolon (grossly dilated bowel), colonic perforation and death. Research suggests that both strain characteristics and the host's immune response influence CDI severity, recurrence risk and mortality [7] [8] [9] . Several advances have contributed to a new understanding of CDI. The epidemiology of CDI is now recognized to be heterogeneous in terms of incidence and strain types reflecting different stages of epidemic spread 10 . Novel fingerprinting techniques, notably whole-genome sequencing (WGS) and multi-locus variable-number tandem-repeat analysis (MLVA), have indicated that C. difficile can be acquired from a wide range of sources 11 , possibly including undiag nosed symptomatic cases, asymptomatic carriers (including infants), animals and food. Historically, CDI diagnosis has been complicated by the wide range of commercial tests available, and the different bac terial targets detected. In this Review, we summarize the key advancements in CDI epidemiology, diagnosis and understanding of transmission.
C. difficile epidemiology C. difficile was first identified as a pathogen related to antibiotic-associated diarrhoea in the late 1970s 12 . In the last decade of the twentieth century, CDI incidence escalated 13 , becoming a well-publicized cause of hospital-acquired infection in developed countries. From 2000 onwards, there was a further increase in CDI dominated by epidemic strains with increased pathogenicity, leading to high transmission rates, increased severity and greater mortality 14 . Today, on average, seven CDI cases occur for every 10,000 overnight patient stays in European hospitals 15 . The incidence is similar in the USA where C. difficile is the leading cause of hospital-associated infection, with an estimated 14,000 deaths each year 16, 17 . Approximately 4-10% of patients are colonized with toxigenic C. difficile on admission to a health-care facility; this proportion rises during their stay within the facility, but is extremely variable between institutions, regions and countries [18] [19] [20] . The risk of acquisition is known to increase with proximity to a symptomatic case, increasing age and longer admissions 21, 22 . In the past decade, the proportion of CDI occurring in patients outside the hospital setting has increased, suggesting endemicity in the wider community, not just in hospital attendees 23 . Studies have shown that communityassociated CDI is more likely to affect younger, healthier patients who are less likely to have been exposed to antibiotics compared with hospital-acquired cases [23] [24] [25] [26] [27] . A large US study published in 2015 (15,451 cases of CDI in 14,453 patients in 2011) demonstrated 48 community cases per 100,000 population, an incidence higher than previously reported 28 . In this study, a two-thirds of CDIs were associated with health-care-facilities but only 24.2% of cases became symptomatic during hospitalization. This study might have over-diagnosed cases by using a highly sensitive molecular assay that fails to differentiate between C. diffi cile colonization and disease 29 . However, these data support the view that the boundaries between hospital and community CDI are becoming less distinct.
Global epidemiology
First recognized in 2002, C. difficile BI/NAP1/027 clones (BOX 1) have caused large epidemics across the developed world with substantial morbidity and mortality 10, 14 . In addition to toxins A and B, this strain produces binary toxin (known as C. difficile transferase (CDT)), also produced by a number of other strains (for example, ribotypes 078 and 023) 7, 30 . Infection caused by these binary-toxin-producing strains has been associated with increased disease severity and 30-day mortality (although it is not clear whether it is binary toxin that contributes to adverse outcome or other, as yet unknown, factors) [31] [32] [33] . The incidence of B1/NAP1/027 has fallen in some areas of Western Europe in the past few years (FIG. 2) , due to a reduction in the total incidence of CDI as well as a reduction in the proportion of cases attributed to this strain type 34, 35 . However, B1/NAP1/027 persists in North America and is increasing in other areas, especially Eastern Europe 15, [36] [37] [38] . In Australia, similar binary-toxin-producing strains, such as ribotype 244, have emerged, but, interestingly, C. difficile BI/NAP1/027 has yet to become established [39] [40] [41] . The reasons for this finding are unclear, but might reflect the relative pressures of antimicrobial selection on particular strains. For example, C. difficile BI/NAP1/027 is fluoroquinolone resistant and these antibiotics are infrequently prescribed in Australia 42 . In Asia, non-binary toxin strains such as ribotypes 017, 018 and 014 remain dominant 43 . Further understanding of global CDI epidemiology is hindered by a lack of surveillance, especially in the developing world.
In the UK, where CDI surveillance is mandatory, the prevalence of C. difficile BI/NAP1/027 has markedly decreased since 2007 (REF. 34) (FIG. 2) . This strain has not been superseded by an alternative dominant strain, but, instead, a picture of increasing diversity of strains has emerged 34 . Such heterogeneity is well documented elsewhere; a review of six US centres demonstrated 98 ribotypes in 720 toxigenic isolates 44 and an Australian study showed 32 ribotypes in 70 samples 45 . Such observations might simply reflect the epidemiology of C. difficile before the emergence of successful clones.
Using C. difficile typing C. difficile strains can be differentiated by a variety of typing techniques
, which can be used to scrutinize epidemiologically linked cases. However, challenges arise when attempting to standardize these techniques between laboratories, particularly when typing methods depend on gel banding patterns (for example, pulsed-field gel electrophoresis (PFGE)). Multi-locus sequence typing (MLST), described by both Griffiths et al. 46 and Lemee et al. 47 in 2010, is a typing strategy that overcomes these challenges by sequencing multiple housekeeping gene fragments and using an Internet-accessible database to interpret results. MLST has the additional benefit of grouping strains into 'clades' based on common molecular lineage. A study examining CDI outcomes based on clades demonstrated interesting differences in disease severity and mortality; 25% 14-day mortality in clade 5 (ST11, ribotype 078) versus 7% in clade 3 (ST22/5, ribotype 023) 8 .
Key points
• Clostridium difficile infection (CDI) is a continually evolving global health-care problem • Community-onset CDI is increasing and multiple potential reservoirs of infection exist including environmental sources, animals, asymptomatic patients and symptomatic patients • Highly discriminatory typing techniques such as whole-genome sequencing and multi-locus variable-number tandem-repeat analysis offer the potential for illuminating previously under-recognized routes of C. difficile transmission • The optimal approach to sampling and testing for CDI remains a contentious issue • Multi-step algorithms are recommended to improve diagnostic sensitivity and specificity
Toxin production and effects on colonic epithelium Notably, whilst some concordance exists between typing methods (as for strain BI/NAP1/027), there are also key differences that reflect the different aspects of the genome targeted by each technique. Ribotyping uses the 16S-23S intergenic spacer region in the ribosomal RNA gene complex 48 ; it is the preferred C. difficile typing method in Europe and Australia and its use has now increased in North America. MLST and ribotyping have similar discriminatory powers but different ribotypes might be seen as a single strain by MLST, and vice versa 49 . For instance, ribotype 014 falls into a number of sequence types (ST2, ST14, ST50 and ST132) and ST2 includes multiple ribotypes (ribotype 014, 020, 076, 220, 095, 006). Similar problems arise when comparing results from other typing strategies such as PFGE, reactive endonuclease analysis (REA) and MLVA
, therefore hindering investigations into global epidemiology.
New C. difficile typing methods, such as WGS, provide a high level of discrimination between strains, aiding epidemiological investigations over short and long timescales 5, 10, 11 . C. difficile genomic evolution is estimated to occur at a rate of 0.74-1.4 (REFS 11, 49) single nucleotide variants (SNVs) per year, and therefore near identical strains (for example, <2 SNVs apart) in two individuals strongly imply transmission or recent exposure to a common source, whereas strains >10 SNVs apart are highly likely to be distinct 11 . For interpret ation of strains separated by between 3 and 10 SNVs, the relation ship between samples should be considered in the context of the C. difficile evolutionary rate. WGS can also be used to assemble phylogenetic trees to investigate the common origins of clinically rele vant C. difficile strains. As an example, WGS has been used to demonstrate transcontinental spread of two distinct lineages of the BI/NAP1/027 strain 10 . One lineage (FQR1) originated in the north eastern USA and was transmitted to South Korea and Switzerland. A second lineage (FQR2) demonstrated wider spread with multiple transatlantic transmission events between the USA and Europe, some of which led to well-publicized CDI outbreaks in the UK and cases in Austria, Poland and the Netherlands 10 . The spread of both strains was preceded by the acquisition of fluoroquinolone resistance, probably relating to the selection pressure of high-level use of this antibiotic in North America 10 . This study highlights the influence of global travel on the spread of emerging infectious microorganisms and suggests a growing need for an internationally uniform approach to C. difficile typing.
CDI transmission
Both host susceptibility and strain characteristics probably contribute to the probability of effective C. difficile transmission, and subsequent infection, when two individuals come into contact 8, 50 (FIG. 1) . The host variables associated with increased CDI risk are well character ized, and include increasing age, antibiotic use and comorbidities 50 . The character istics leading to the success of particular strains are less well understood.
Host susceptibility to CDI is known to be enhanced by changes in the host intestinal microbiota, often follow ing hospital admission and/or antibiotic exposure 51 . An analysis of the gut microbiome using 16S ribosomal RNA sequencing demonstrated a reduction in the diversity of host bacteria and altered predominant species in patients with CDI compared with healthy individuals or those with asymptomatic C. difficile colonization 52 . Antimicrobial-induced dysbiosis also results in the loss of protective Toll-like receptor signalling, accumulation of pro-inflammatory type 17 T helper cells and increased epithelial permeability 53 . Thus, subsequent infection with C. difficile leads to toxin-mediated epithelial injury and perpetuation of the pro-inflammatory response 6 .
Sporulation and germination
Currently, we have a limited understanding of the reasons why some C. difficile strains have led to large transatlantic epidemics (such as BI/NAP1/ribotype 027), whereas others remain at a local or sporadic level. Several explanations for this 'hypervirulence' have been proposed 7, [54] [55] [56] , and it seems likely that pathogenic factors such as germination, sporulation, epithelial adherence and toxin production could influence the success of some strains.
C. difficile spores are a key feature in transmission (FIG. 1) . Once ingested, spores interact with small molecular germinants, such as bile acids 57, 58 , triggering a series of events committing the spore to germinate into toxinproducing bacteria. A germination-specific protease, CspC, has been shown to have an active and essential role in germination by functioning as the C. difficile bile acid germinant receptor 59 . Data has also begun to elucidate the activity of Spo0A the master regulator of sporulation, which controls the transition of the bac terium into the spore form 60, 61 . Spo0A has been implicated in controlling toxin gene expression 62 , intestinal colonization and disease in mice [63] [64] [65] . Early evidence indicates that Spo0A might vary between ribotypes 62 , but further research is required to confirm the influence this factor might have on transmission and clinical disease.
Toxins, immunity and disease
Investigations seeking to link quantitative toxin production with C. difficile virulence have not been conclusive 65 .
The clinical impact of a particular C. difficile strain is related not only to its pathogenicity, but also to the host immune response to toxin. Toxins A and B stimulate the release of multiple pro-inflammatory cytokines and chemokines -for example, IL-1β, TNF, IL-8, IL-12, IL-18, IL-23, C-C motif chemokine 4 (also known as ▶ macrophage inflammatory protein 1β), C-X-C motif chemokine 2 (also known as macrophage inflammatory protein 2α) and leptin -from epithelial cells and mucosal immune cells [66] [67] [68] [69] . This inflammatory response is a major determinant of disease severity 70, 71 and has been shown to correlate with persistent diarrhoea and poor clinical outcome 8, 72 . Importantly, toxins A and B are themselves targets of immune recognition. Antibodymediated responses to toxins have an important role in determining asymptomatic carriage and predisposition to recurrent infection 71 . Symptomless carriers of toxigenic C. difficile and those who have had a single episode of CDI show more robust antitoxin immune responses than those with symptomatic and recurrent disease 73, 74 . Circulating TcdA-specific or TcdB-specific memory B cells have been detected after CDI, strengthening the evidence for the importance of the humoral immune response against both toxins 75 .
Hospital-acquired infection
Control of CDI has conventionally centred on symptomatic cases, especially during hospital outbreaks, because these are the most recognizable sources of transmission. Although the exact temporal relationship between antibiotic exposure, spore exposure and symptom onset is unknown in most instances, a study published in 2012 found that most infectious periods for potential donors to support transmission of C. difficile were ≤1 week (65%), with only 10% >8 weeks 2 . Most incubation periods in recipients were ≤4 weeks (61%), with few >12 weeks (13%) 2 . CDI transmission between symptomatic patients has been studied in Oxfordshire, UK, using detailed epidemiological data and WGS of consecutive isolates 11 . The analysis revealed that 45% of new cases were genetically distinct from all previous cases and only 13% of infected individuals had recent ward contact with a previous sequence matched case (≤2 SNVs) 11 . Many genetically matched cases showed no epidemiological relationship (either hospital or community-associated), which suggests alternative sources of infection 11 . This study used a suboptimal diagnostic test (a toxin enzymeimmunoassay), which lacks sensitivity 11, 76 , and it is likely that a proportion of true CDI cases will have remained undiagnosed. However, these findings have been confirmed by preliminary results from a UK study using a reference standard diagnostic test 77 and there are probably alternative sources of C. difficile in the healthcare setting, potentially including untested symptomatic patients, asymptomatic patients, environmental contamination and health-care workers.
The contribution of asymptomatic carriers to transmission has been confirmed in a study published in 2013 from Pittsburgh, USA, in which 10.4% of inpatients carried C. difficile regardless of their symptom profile 19 . MLVA typing (BOX 1) showed that one-third of diagnosed CDI cases had been in recent contact (within 30 days) with a symptomatic patient, whereas another third had had contact only with an asymptomatic C. difficile carrier 19 . This finding confirms earlier work suggesting a major role for asymptomatic patients in transmitting C. difficile 4 . Larger multicentre studies are needed to fully appreciate the effect of asymptomatic colonization and/or carriage on transmission associated with health-care facilities. A meta-analysis published in 2015 of North American studies suggests that toxigenic C. difficile carriage on hospital admission increases the risk of subsequent CDI sixfold (21.8% versus 3.4%, P = 0.03), contrary to previous understanding that carriage reduced CDI risk 24 . Notably, at present, no proven intervention to elimin ate C. difficile in such individ uals is available, and the resource implications for global sampling and source isolation of asymptomatic patients are daunting.
Another possible source of CDI transmission is health-care workers. Factors such as poor hand hygiene have previously been shown to play a part in CDI transmission 78 . Conversely, asymptomatic intestinal C. difficile carriage in health-care workers is generally uncommon; an Australian study of 128 doctors, nurses and allied health staff failed to demonstrate C. difficile in any participant despite >40% reporting contact with CDI in the 6 weeks before testing 79 . This finding, repeated in a 2015 Swedish study 80 , might reflect colonization resistance of healthy gut microbiota and/or effective infection control practices. However, the clinical impact of transient gut colonization is largely unknown and would not necessarily have been detected in these small point prevalence studies.
Taken together, these data suggest that source isolation of symptomatic patients with CDI and control of epidemic strains, although essential interventions, might no longer be sufficient to further reduce the burden of disease. Further investigation of alternative sources of CDI in the hospital setting is necessary, with a focus on asymptomatic and untested patients. Alternative approaches, such as controlling exposure to anti biotics and reducing the susceptibility of patients to CDI (for example, by vaccination) might also be required.
Box 1 | Clostridium difficile typing methods and ribotype 027/NAP1/BI/ST1
The lack of a universally accepted typing strategy has limited the comparison of strain patterns between countries and continents delaying a comprehensive global understanding of C. difficile epidemiology. Commonly used methods for C. difficile typing include ribotyping, pulsed-field gel electrophoresis (PFGE), restriction endonuclease analysis (REA), multi-locus sequence typing (MLST) and multi-locus variable-number tandem-repeat analysis (MLVA) 113 . Each technique is reported with its own nomenclature, thus ribotype 027 is also known as NAP1 (PFGE), BI (REA) and ST1 (MLST). The various typing methods have different relative discriminatory powers; REA and MLVA show greater discrimination than ribotyping or MLST, which in turn provide greater power to separate strains than PFGE 113, 114 . Since 2010, whole-genome sequencing (WGS) has been increasingly used as a highly discriminatory technique enabling phylogenetic analysis of C. difficile strains to establish genetic relatedness and historical lineages 5, 10, 11 . WGS is similar in power to MLVA, but can also demonstrate the presence of specific genes and mutations 114 . High-throughput technologies will soon allow WGS to be applied to clinical situations within realistic time and cost constraints 115 . Current limitations of WGS include the high acquisition cost of sequencing platforms, the complexity of sequence analysis and the need to improve nomenclature for use in routine practice; thus, a consistent global approach is required 10, 116 . Other technologies, such as mass spectrometry (e.g. MALDI-TOF), provide the potential for rapid C. difficile typing, but currently lack discriminatory power compared with routine methods 117 .
Community-associated and community-onset CDI Human reservoirs. Community-associated infections (CA-CDI) are typically defined as those with symptom onset in the community (or within 48 h of hospital admission) without a history of hospitalization within the previous 12 weeks 81 . Testing for CDI in the community often lacks consistency and low diagnostic suspicion can lead to missed cases; one study conducted in the Netherlands demonstrated that only 40% of community CDI cases are successfully detected 82 . CA-CDI should not be confused with 'community-onset' CDI, a term encompassing both CA-CDI, indeterminate CDI and community-onset health-care-facility-associated CDI
. A large US surveillance study published in 2015 demonstrated that over a half of their CDI cases were community-onset 28 . This study estimated that twothirds of hospital-associated cases had symptom onset in the community, split equally between nursing home residents and patients in their own homes. The majority of community-onset hospital acquired cases occur soon after discharge, suggesting either hospital acquisition or possibly the use of inciting antibiotics during hospital admissions 83, 84 . Additionally, ~25% of patients with true CA-CDI are hospitalized for treatment 23 ; thus, strains are likely to circulate frequently between hospital and community settings. Published data from geographical regions using ribotyping to discriminate C. difficile strains are depicted from Davies et al. 15 (n = 1,211), Kim et al. 122 (n = 140), Huang et al. 123 (n = 75), Eyre et al. 40 (n = 746), Plaza-Garrido et al. 124 (n = 81), Waslawski et al. 44 (n = 720) and a Public Health England report (n = 5,451) 34 . The pie charts demonstrate the variation in the worldwide distribution of common ribotypes; there is an increased prevalence of ribotype 027 (BI/NAP1) in North America and Europe compared with other areas. This strain is seen only rarely in Asia and elsewhere, though large data sets are very limited from these regions. Ribotype 027 is not seen in Australia; however, a similar binary toxin strain (ribotype 244) has been seen here since 2010. *Ribotype 244 represented 2% of C. difficile strains in Australia. 
Ribotypes
More than one-half of patients with CA-CDIs have outpatient health-care exposure in the weeks before infection 26 . CA-CDI is also well-recognized in residents of long-term care (LTC) facilities 85 (LTC cases are classified as health-care associated in some countries, including the USA), with hospital strains being regularly introduced by both asymptomatic and symptomatic attendees 86, 87 . A meta-analysis including nine studies, mainly from North America, demonstrated a 14.8% rate of asymptomatic carriage of toxigenic strains in LTC residents 87 . Colonization with toxigenic strains was associated with previous CDI, prior hospitalization and antimicrobial use. Previously, a survey in Germany demonstrated an approximate fivefold increase in C. difficile colonization of LTC residents compared with elderly people living in their own homes 85 . Further data are needed on the importance of both outpatient department visits and LTC residence in CA-CDI transmission; in both instances, CDI incidence is likely to be dependent on the susceptibility of other attendees.
Asymptomatic C. difficile carriage in infants is another potential reservoir for CDI. Contact with children <2 years old has previously been shown to be a risk factor for CA-CDI 88 . Furthermore, two small studies have shown 22-45% of healthy infants to be colonized with toxigenic or non-toxigenic C. difficile at a single point in time, with the majority of these infants being affected during the first year of life 89, 90 . Pathogenic strains were retrieved in both studies, but ribotypes seen most frequently in adult CDI (for example, ribotypes 027/078) were not seen in healthy children. However, not all studies have demonstrated the association between infants and CDI 82 .
Environmental reservoirs. Environmental sources could be relevant to CA-CDI. Toxigenic and non-toxigenic C. difficile strains can be recovered from the faeces of piglets, cattle, horses and poultry, risking transmission to humans via direct contact, food and the environment 27, 91 . Studies in the Netherlands, where high-density pig farming is present in some parts of the country, have demonstrated the potential spread of C. difficile between farm animals and humans 92, 93 . The reported prevalence of C. difficile in 'off-the-shelf ' foods is generally low but extremely variable (0-42%), with ground meat, shellfish, vegetables and pre-packed salads most commonly contaminated [91] [92] [93] [94] . No food-related outbreaks have been reported.
C. difficile has also been recovered from water, soil 95 and household environs; one small US study demonstrated toxigenic C. difficile on 25 of 63 (39.7%) of shoe swabs 96 . However, the relative importance of exposure to infants, animals and the environment has remained elusive, perhaps reflecting the fact that the majority of the population lacks vulnerability to CDI due to colonization resistance provided by healthy bowel microbiota.
In summary, it is probable that community and hospital exposure to C. difficile is frequent and the outcomes following spore acquisition relate to the host microbiota, host immune function and strain virulence. 
Box 3 | Clostridium difficile infection diagnostic tests

Reference standards
The two reference tests for C. difficile have different bacterial targets. Cytotoxigenic culture demonstrates the presence of C. difficile isolates with the ability to produce toxin when cultured, whereas the cell cytotoxicity assay (CTA) detects the presence of toxin B (and toxin A) in stool. Thus, cytotoxigenic culture demonstrates the presence of a toxigenic strain of C. difficile, which is important for infection control purposes but does not necessarily imply infection, whereas CTA is more closely related to disease but might miss individuals with the potential to transmit toxigenic strains to others. CTA yields fewer positive tests than cytotoxigenic culture by ignoring toxigenic strains not currently producing toxin in the patient. CTA positivity has been shown to correlate more closely with clinical outcome and mortality 76 .
Toxin enzyme immunoassays (EIAs)
EIAs directly detect C. difficile toxin (A or B) in stool samples. EIAs are rapid, simple to use and inexpensive, which has led to their widespread use. However, they have poor diagnostic accuracy for CDI as single tests (sensitivity 60-92%) 76 . Thus, the use of toxin EIAs as stand-alone tests is no longer recommended 109 .
Glutamate dehydrogenase (GDH) and nucleic acid amplification tests (NAAT)
GDH testing detects a cell wall antigen (the GDH enzyme), which is produced by toxigenic and non-toxigenic strains of C. difficile 118 . GDH tests have high sensitivity but low specificity 76, 118 . A growing number of NAATs for the detection of toxin genes are now available 119 . The two methods used are real-time PCR targeting the toxin genes (tcdA or tcdB) and loop-mediated isothermal amplification of DNA 29, 120 . NAATs have high sensitivity compared with cytotoxigenic culture 108, 121 . GDH tests and NAATs are widely used but neither detects C. difficile toxins so they cannot differentiate between asymptomatic carriage and true infection. Clinical correlation of positive results or further testing is required.
Further research into CDI acquisition and transmission will be challenging due to the ubiquitous nature of this bacterium, but WGS has the potential to accurately link environmental reservoirs to human infection in the near future.
CDI diagnosis
Targets for C. difficile detection CDI research has been complicated by the wide range of diagnostic tests available
, inconsistent use of reference standards and a lack of agreement in the clinical criteria used for sampling 97, 98 . C. difficile produces two closely related proteins to elicit its toxic effect: toxin A and toxin B. Their corresponding genes (tcdA and tcdB) are encoded by the Pathogenicity Locus (PaLoc), a chromo somally integrated DNA sequence that is variably present among strains 99, 100 . Strains lacking the PaLoc are not associated with disease 100, 101 . However, horizontal gene transfer of the PaLoc has the potential to convert non-toxigenic strains into toxin-producers 100 . Tests for C. difficile infection can detect the bacterium itself, the presence of toxin or the capability of a particular strain to produce toxin. Two reference standard tests are in current use worldwide
: one for detection of toxin-producing potential (cytotoxigenic), and the other for the detection of toxin (cell cytotoxicity assay, CTA). Importantly, new tests for CDI must use the appropriate reference standard to create accurate sensitivity and/or specificity data.
Different C. difficile diagnostic tests have been shown to correlate variably with clinical outcome [102] [103] [104] . A prospective observational study by Polage et al. 105 demonstrated that detection of toxin genes alone (nucleic acid amplification tests, or NAATs) over-diagnosed clinically relevant CDI. Toxin was detected in only half of the NAAT-positive patients; toxin-negative patients had a similar symptom duration as patients without toxigenic C. difficile, whereas toxin-positive patients had a markedly increased risk of CDI complications (7.6% versus 0% in toxin-negative patients; P <0.001) and CDI-related death (8.4% versus 0.6% in toxin negative group; P = 0.001) 105 . This study is particularly insightful because NAAT has been adopted by many centres within the USA, increasing CDI rates by 50-100% in some laboratories 105 . Notably, the study also confirmed the results of a large, multicentre, prospective study published in 2013, which compared 12 test-reference standard combinations, including assays for all three bacteriological targets (cell wall antigen, toxin genes and toxin) 76 . Planche et al. 76 found that positive CTAs were associated with increased all-cause mortality (16.6% at 30 days). Mortality was similar in patients with NAAT-positive-CTA-negative (9.7%) samples and those for whom both tests were negative (8.6%), suggesting that the presence of toxin itself is more indicative of mortality risk than carriage of a strain with toxin-producing potential 76 . Thus, tests detecting C. difficile toxigenic potential, rather than toxin, will probably overdiagnose CDI with possible wide-ranging consequences, including inadequate investigation of alternative causes of diarrhoea and false elevation of an institution's healthcare-associated infection incidence. Ironically, another such consequence is overtreatment of diarrhoea with antibiotics leading to perpetuation of gut dysbiosis, and so risking subsequent CDI.
Despite the association of CDI diagnostic test results and mortality in study populations, no such assay can be guaranteed to correlate with clinical outcome in an individual; patients with a positive toxin enzyme immunoassay can be asymptomatic and severe infection or death can occur in patients with negative toxin enzyme immunoassay results 20, 73, 106, 107 . Thus, clin ical judgement is always required in conjunction with test results to diagnose CDI accurately. Clinical strategies to minimize inappropriate testing are also needed to avoid the risks associated with CDI treatment in asymptomatic carriers. 
Two-step diagnostic algorithms
Owing to the failure of single commercial tests to accurately diagnose CDI, two-step algorithms for CDI diagnosis have been recommended for several years 81, 108 (FIG. 3) . Forthcoming revised European guidelines on CDI diagnosis recommend two-stage testing, comprising a sensitive (screening) test for C. difficile (that is, a glutamate dehydrogenase test or NAAT), followed by a toxin test, in line with UK practice (M. H. Wilcox, personal communication). Algorithm design requires consideration of cost, speed, sensitivity and specificity. Although the optimal diagnostic strategy is still under debate, data suggest that using a high sensitivity test (glutamate dehydrogenase antigen or NAAT) to screen for C. difficile can yield a rapid result with very high negative predictive value 109, 110 . This approach enables swift communication of negative results to clinical teams. If the screening test is positive, a second C. difficile toxin test (toxin enzyme immunoassay or CTA) provides speci ficity for CDI. If a two-step approach gives discordant results (for example, a positive glutamate dehydrogenase test followed by a negative toxin test) then a third test can be used to increase sensitivity, such as NAAT. Alternatively, it is reasonable to manage the patient as if infection is present if there is a strong clinical suspicion of CDI. Despite guidelines from the past few years that recommend glutamate dehydro genase or NAAT testing followed by toxin enzyme immunoassays [108] [109] [110] , only 29% of European labora tories are using such a combination of tests, with 45% still using a single test 15 .
Sampling patients for CDI
The correct clinical criteria for sampling should be used to identify true cases of CDI. A US study found that over one-third of clinician-requested tests did not meet the criteria for 'significant diarrhoea' , meaning that the detection of C. difficile in these patients would be unlikely to indicate disease 98 . Equally, there are also examples of patients with CDI being missed due to a failure to test them, such as a Spanish point prevalence study that tested all unformed stools, regardless of whether the clinician had requested C. difficile testing, and found twothirds of positive samples would have been missed 111 . Furthermore, a pan-European study in 482 hospitals across 20 countries found that one-quarter of all patients with toxigenic C. difficile were missed due to inadequate sampling and/or testing strategies 15 . Together, these data confirm that despite the prominence of CDI as a clinical threat, considerable challenges remain when trying to correctly recognize and diagnose this infection.
As mentioned previously, 7-10% of asymptomatic patients are colonized with toxigenic C. difficile on arrival to hospital 19, 20, 24 . Non-infectious diarrhoea is frequent in hospitalized patients and clinical differentiation between infectious and non-infectious symptoms is unreliable 112 , making it difficult to know who to test. To fully understand and manage CDI, it is important to examine the interrelationship between diagnostic tests and the wide-ranging spectrum of C. difficile carriage and disease. Then, it will be possible to identify patients who require no intervention (that is, those carry ing non-toxigenic strains), those who pose an infection risk to others (that is, those carrying toxigenic strains) and symptomatic patients requiring treatment (that is, those positive for C. difficile toxin with clin ical evidence of infection). A clear and unified global approach, separately defining infectious individuals and clinical cases, would allow improved understanding of the disease epidemiology as well as empowering clinicians to make informed decisions on who to treat and how best to utilize infection control resources.
Conclusions
Novel C. difficile strains have been shown to rapidly emerge and spread across countries and continents with global health implications. The reasons for the increased transmissibility of certain strains might relate to a number of factors including antibiotic resistance, sporulation and toxin production. Improved surveillance of C. difficile, in particular use of a unifying typing strategy such as WGS, will probably revolutionize our understanding of the epidemiology of CDI. In particular, future research will help determine the main transmission routes and sources of C. difficile in non-outbreak settings and help to identify methods to reduce CDI incidence in populations at risk. However, further reduction in CDIs will be challenging as evidence suggests that asymptomatic carriage could play a prominent part in transmission and, unlike in other hospital-associated infections such as methicillin-resistant Staphylococcus aureus, effective screening and decolonization strategies are not in current clinical practice.
Over the past decade, choosing 'who to sample' and 'how to test' for CDI have been contentious issues for clinicians. The answers to these important questions are likely to substantially influence local CDI epidemiology, diagnosis and treatment. Unlike the ease of modern rapid identification strategies for other microorganisms (such as mass spectrometry), C. difficile diagnosis is complicated by the need to differentiate toxin-producing from non-toxigenic strains. Evidence now suggests that using any single test as a blunt tool for both diagnosis and assessment of transmission risk is too simplistic. Improved diagnostics for CDI are needed to identify who is truly infected with, as opposed to colonized by, C. difficile. Better (more sensitive and specific) toxin detection methods would help. Improved real-time CDI case ascertainment will mean that the most appropriate treatment option(s) can be targeted at the right patients while onward transmission can be interrupted by identification of those carrying toxigenic strains.
